Brief: Australia's Therapeutic Goods Administration Says Seqirus To Discontinue Benpen Injection Products
27/05/2026 09:01
BRIEF-Australia's Therapeutic Goods Administration Says Seqirus To Discontinue Benpen Injection Products May 27 (Reuters) - Australia's Therapeutic Goods Administration:
SEQIRUS NOTIFIED TO DISCONTINUE ALL STRENGTHS OF BENPEN INJECTION PRODUCTS PROGRESSIVELY
ALTERNATIVE AUSTRALIAN-REGISTERED BENZYLPENICILLIN SODIUM INJECTION BRANDS EXPECTED TO BE AVAILABLE IN FUTURE
SUPPLY OF THESE BENZYLPENICILLIN SODIUM INJECTION PRODUCTS WILL CONTINUE UNTIL STOCK IS EXHAUSTED
BENPEN INJECTION PRODUCTS TO BE DISCONTINUED PROGRESSIVELY STARTING WITH 600MG STRENGTH FROM 30 NOV DUE TO COMMERCIAL REASONS
Further company coverage: CSL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX